0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Pulmonary Fibrosis Drug Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-0W8392
Home | Market Reports | Health| Health Conditions
Global and Japan Pulmonary Fibrosis Drug Market Insights Forecast to 2027
BUY CHAPTERS

Global Pulmonary Fibrosis Drug Market Research Report 2025

Code: QYRE-Auto-0W8392
Report
July 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Pulmonary Fibrosis Drug Market Size

The global market for Pulmonary Fibrosis Drug was valued at US$ 4747 million in the year 2024 and is projected to reach a revised size of US$ 6648 million by 2031, growing at a CAGR of 5.0% during the forecast period.

Pulmonary Fibrosis Drug Market

Pulmonary Fibrosis Drug Market

Pulmonary fibrosis is a lung disorder characterized by damage or scarring of the lung tissue. Once the tissue is damaged, it obstructs the passageway for air and thus hinders the normal functioning of the lungs. It is usually caused as a result of certain medical conditions, exposure to toxins, pollutants or radiation or by certain medications.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Pulmonary Fibrosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Fibrosis Drug.
The Pulmonary Fibrosis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pulmonary Fibrosis Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Fibrosis Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Pulmonary Fibrosis Drug Market Report

Report Metric Details
Report Name Pulmonary Fibrosis Drug Market
Accounted market size in year US$ 4747 million
Forecasted market size in 2031 US$ 6648 million
CAGR 5.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc., Biogen, Galapagos NV
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Pulmonary Fibrosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Pulmonary Fibrosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Pulmonary Fibrosis Drug Market growing?

Ans: The Pulmonary Fibrosis Drug Market witnessing a CAGR of 5.0% during the forecast period 2025-2031.

What is the Pulmonary Fibrosis Drug Market size in 2031?

Ans: The Pulmonary Fibrosis Drug Market size in 2031 will be US$ 6648 million.

Who are the main players in the Pulmonary Fibrosis Drug Market report?

Ans: The main players in the Pulmonary Fibrosis Drug Market are Boehringer Ingelheim, Roche, FibroGen, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, MediciNova, Inc., Genentech, Inc., Cipla Inc., Biogen, Galapagos NV

What are the Application segmentation covered in the Pulmonary Fibrosis Drug Market report?

Ans: The Applications covered in the Pulmonary Fibrosis Drug Market report are Hospital, Clinic

What are the Type segmentation covered in the Pulmonary Fibrosis Drug Market report?

Ans: The Types covered in the Pulmonary Fibrosis Drug Market report are Pirfenidone, Nintedanib

Recommended Reports

Pulmonary & Respiratory

Lung & Cancer Drugs

Fibrosis & Related Drugs

1 Pulmonary Fibrosis Drug Market Overview
1.1 Product Definition
1.2 Pulmonary Fibrosis Drug by Type
1.2.1 Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Pirfenidone
1.2.3 Nintedanib
1.3 Pulmonary Fibrosis Drug by Application
1.3.1 Global Pulmonary Fibrosis Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Pulmonary Fibrosis Drug Market Size Estimates and Forecasts
1.4.1 Global Pulmonary Fibrosis Drug Revenue 2020-2031
1.4.2 Global Pulmonary Fibrosis Drug Sales 2020-2031
1.4.3 Global Pulmonary Fibrosis Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Pulmonary Fibrosis Drug Market Competition by Manufacturers
2.1 Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Pulmonary Fibrosis Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Pulmonary Fibrosis Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pulmonary Fibrosis Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pulmonary Fibrosis Drug, Product Type & Application
2.7 Global Key Manufacturers of Pulmonary Fibrosis Drug, Date of Enter into This Industry
2.8 Global Pulmonary Fibrosis Drug Market Competitive Situation and Trends
2.8.1 Global Pulmonary Fibrosis Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Pulmonary Fibrosis Drug Players Market Share by Revenue
2.8.3 Global Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Pulmonary Fibrosis Drug Market Scenario by Region
3.1 Global Pulmonary Fibrosis Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Pulmonary Fibrosis Drug Sales by Region: 2020-2031
3.2.1 Global Pulmonary Fibrosis Drug Sales by Region: 2020-2025
3.2.2 Global Pulmonary Fibrosis Drug Sales by Region: 2026-2031
3.3 Global Pulmonary Fibrosis Drug Revenue by Region: 2020-2031
3.3.1 Global Pulmonary Fibrosis Drug Revenue by Region: 2020-2025
3.3.2 Global Pulmonary Fibrosis Drug Revenue by Region: 2026-2031
3.4 North America Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.4.1 North America Pulmonary Fibrosis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Pulmonary Fibrosis Drug Sales by Country (2020-2031)
3.4.3 North America Pulmonary Fibrosis Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.5.1 Europe Pulmonary Fibrosis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Pulmonary Fibrosis Drug Sales by Country (2020-2031)
3.5.3 Europe Pulmonary Fibrosis Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pulmonary Fibrosis Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Pulmonary Fibrosis Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Pulmonary Fibrosis Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.7.1 Latin America Pulmonary Fibrosis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Pulmonary Fibrosis Drug Sales by Country (2020-2031)
3.7.3 Latin America Pulmonary Fibrosis Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pulmonary Fibrosis Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Pulmonary Fibrosis Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Pulmonary Fibrosis Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pulmonary Fibrosis Drug Sales by Type (2020-2031)
4.1.1 Global Pulmonary Fibrosis Drug Sales by Type (2020-2025)
4.1.2 Global Pulmonary Fibrosis Drug Sales by Type (2026-2031)
4.1.3 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2020-2031)
4.2 Global Pulmonary Fibrosis Drug Revenue by Type (2020-2031)
4.2.1 Global Pulmonary Fibrosis Drug Revenue by Type (2020-2025)
4.2.2 Global Pulmonary Fibrosis Drug Revenue by Type (2026-2031)
4.2.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2020-2031)
4.3 Global Pulmonary Fibrosis Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Pulmonary Fibrosis Drug Sales by Application (2020-2031)
5.1.1 Global Pulmonary Fibrosis Drug Sales by Application (2020-2025)
5.1.2 Global Pulmonary Fibrosis Drug Sales by Application (2026-2031)
5.1.3 Global Pulmonary Fibrosis Drug Sales Market Share by Application (2020-2031)
5.2 Global Pulmonary Fibrosis Drug Revenue by Application (2020-2031)
5.2.1 Global Pulmonary Fibrosis Drug Revenue by Application (2020-2025)
5.2.2 Global Pulmonary Fibrosis Drug Revenue by Application (2026-2031)
5.2.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2020-2031)
5.3 Global Pulmonary Fibrosis Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Boehringer Ingelheim
6.1.1 Boehringer Ingelheim Company Information
6.1.2 Boehringer Ingelheim Description and Business Overview
6.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio
6.1.5 Boehringer Ingelheim Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Pulmonary Fibrosis Drug Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 FibroGen, Inc.
6.3.1 FibroGen, Inc. Company Information
6.3.2 FibroGen, Inc. Description and Business Overview
6.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.3.5 FibroGen, Inc. Recent Developments/Updates
6.4 Merck & Co., Inc.
6.4.1 Merck & Co., Inc. Company Information
6.4.2 Merck & Co., Inc. Description and Business Overview
6.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio
6.4.5 Merck & Co., Inc. Recent Developments/Updates
6.5 Bristol-Myers Squibb Company
6.5.1 Bristol-Myers Squibb Company Company Information
6.5.2 Bristol-Myers Squibb Company Description and Business Overview
6.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio
6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.6 MediciNova, Inc.
6.6.1 MediciNova, Inc. Company Information
6.6.2 MediciNova, Inc. Description and Business Overview
6.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.6.5 MediciNova, Inc. Recent Developments/Updates
6.7 Genentech, Inc.
6.7.1 Genentech, Inc. Company Information
6.7.2 Genentech, Inc. Description and Business Overview
6.7.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio
6.7.5 Genentech, Inc. Recent Developments/Updates
6.8 Cipla Inc.
6.8.1 Cipla Inc. Company Information
6.8.2 Cipla Inc. Description and Business Overview
6.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio
6.8.5 Cipla Inc. Recent Developments/Updates
6.9 Biogen
6.9.1 Biogen Company Information
6.9.2 Biogen Description and Business Overview
6.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Biogen Pulmonary Fibrosis Drug Product Portfolio
6.9.5 Biogen Recent Developments/Updates
6.10 Galapagos NV
6.10.1 Galapagos NV Company Information
6.10.2 Galapagos NV Description and Business Overview
6.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Galapagos NV Pulmonary Fibrosis Drug Product Portfolio
6.10.5 Galapagos NV Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pulmonary Fibrosis Drug Industry Chain Analysis
7.2 Pulmonary Fibrosis Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pulmonary Fibrosis Drug Production Mode & Process Analysis
7.4 Pulmonary Fibrosis Drug Sales and Marketing
7.4.1 Pulmonary Fibrosis Drug Sales Channels
7.4.2 Pulmonary Fibrosis Drug Distributors
7.5 Pulmonary Fibrosis Drug Customer Analysis
8 Pulmonary Fibrosis Drug Market Dynamics
8.1 Pulmonary Fibrosis Drug Industry Trends
8.2 Pulmonary Fibrosis Drug Market Drivers
8.3 Pulmonary Fibrosis Drug Market Challenges
8.4 Pulmonary Fibrosis Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Pulmonary Fibrosis Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Pulmonary Fibrosis Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Pulmonary Fibrosis Drug Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Pulmonary Fibrosis Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Pulmonary Fibrosis Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Pulmonary Fibrosis Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Pulmonary Fibrosis Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Pulmonary Fibrosis Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Pulmonary Fibrosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Fibrosis Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Pulmonary Fibrosis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Pulmonary Fibrosis Drug Sales by Region (2020-2025) & (K Units)
 Table 18. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Pulmonary Fibrosis Drug Sales by Region (2026-2031) & (K Units)
 Table 20. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Pulmonary Fibrosis Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Pulmonary Fibrosis Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Pulmonary Fibrosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Pulmonary Fibrosis Drug Sales by Country (2020-2025) & (K Units)
 Table 27. North America Pulmonary Fibrosis Drug Sales by Country (2026-2031) & (K Units)
 Table 28. North America Pulmonary Fibrosis Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Pulmonary Fibrosis Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Pulmonary Fibrosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Pulmonary Fibrosis Drug Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Pulmonary Fibrosis Drug Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Pulmonary Fibrosis Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Pulmonary Fibrosis Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Pulmonary Fibrosis Drug Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Pulmonary Fibrosis Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Pulmonary Fibrosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Pulmonary Fibrosis Drug Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Pulmonary Fibrosis Drug Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Pulmonary Fibrosis Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Pulmonary Fibrosis Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Pulmonary Fibrosis Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Pulmonary Fibrosis Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Pulmonary Fibrosis Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Pulmonary Fibrosis Drug Sales (K Units) by Type (2020-2025)
 Table 51. Global Pulmonary Fibrosis Drug Sales (K Units) by Type (2026-2031)
 Table 52. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Pulmonary Fibrosis Drug Sales (K Units) by Application (2020-2025)
 Table 61. Global Pulmonary Fibrosis Drug Sales (K Units) by Application (2026-2031)
 Table 62. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Pulmonary Fibrosis Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2026-2031)
 Table 70. Boehringer Ingelheim Company Information
 Table 71. Boehringer Ingelheim Description and Business Overview
 Table 72. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Boehringer Ingelheim Pulmonary Fibrosis Drug Product
 Table 74. Boehringer Ingelheim Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Roche Pulmonary Fibrosis Drug Product
 Table 79. Roche Recent Developments/Updates
 Table 80. FibroGen, Inc. Company Information
 Table 81. FibroGen, Inc. Description and Business Overview
 Table 82. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. FibroGen, Inc. Pulmonary Fibrosis Drug Product
 Table 84. FibroGen, Inc. Recent Developments/Updates
 Table 85. Merck & Co., Inc. Company Information
 Table 86. Merck & Co., Inc. Description and Business Overview
 Table 87. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Merck & Co., Inc. Pulmonary Fibrosis Drug Product
 Table 89. Merck & Co., Inc. Recent Developments/Updates
 Table 90. Bristol-Myers Squibb Company Company Information
 Table 91. Bristol-Myers Squibb Company Description and Business Overview
 Table 92. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product
 Table 94. Bristol-Myers Squibb Company Recent Developments/Updates
 Table 95. MediciNova, Inc. Company Information
 Table 96. MediciNova, Inc. Description and Business Overview
 Table 97. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. MediciNova, Inc. Pulmonary Fibrosis Drug Product
 Table 99. MediciNova, Inc. Recent Developments/Updates
 Table 100. Genentech, Inc. Company Information
 Table 101. Genentech, Inc. Description and Business Overview
 Table 102. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Genentech, Inc. Pulmonary Fibrosis Drug Product
 Table 104. Genentech, Inc. Recent Developments/Updates
 Table 105. Cipla Inc. Company Information
 Table 106. Cipla Inc. Description and Business Overview
 Table 107. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Cipla Inc. Pulmonary Fibrosis Drug Product
 Table 109. Cipla Inc. Recent Developments/Updates
 Table 110. Biogen Company Information
 Table 111. Biogen Description and Business Overview
 Table 112. Biogen Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Biogen Pulmonary Fibrosis Drug Product
 Table 114. Biogen Recent Developments/Updates
 Table 115. Galapagos NV Company Information
 Table 116. Galapagos NV Description and Business Overview
 Table 117. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Galapagos NV Pulmonary Fibrosis Drug Product
 Table 119. Galapagos NV Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Pulmonary Fibrosis Drug Distributors List
 Table 123. Pulmonary Fibrosis Drug Customers List
 Table 124. Pulmonary Fibrosis Drug Market Trends
 Table 125. Pulmonary Fibrosis Drug Market Drivers
 Table 126. Pulmonary Fibrosis Drug Market Challenges
 Table 127. Pulmonary Fibrosis Drug Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Pulmonary Fibrosis Drug
 Figure 2. Global Pulmonary Fibrosis Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Pulmonary Fibrosis Drug Market Share by Type: 2024 & 2031
 Figure 4. Pirfenidone Product Picture
 Figure 5. Nintedanib Product Picture
 Figure 6. Global Pulmonary Fibrosis Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Pulmonary Fibrosis Drug Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Global Pulmonary Fibrosis Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Pulmonary Fibrosis Drug Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Pulmonary Fibrosis Drug Sales (2020-2031) & (K Units)
 Figure 13. Global Pulmonary Fibrosis Drug Average Price (US$/Unit) & (2020-2031)
 Figure 14. Pulmonary Fibrosis Drug Report Years Considered
 Figure 15. Pulmonary Fibrosis Drug Sales Share by Manufacturers in 2024
 Figure 16. Global Pulmonary Fibrosis Drug Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Pulmonary Fibrosis Drug Players: Market Share by Revenue in Pulmonary Fibrosis Drug in 2024
 Figure 18. Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Pulmonary Fibrosis Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Pulmonary Fibrosis Drug Sales Market Share by Country (2020-2031)
 Figure 21. North America Pulmonary Fibrosis Drug Revenue Market Share by Country (2020-2031)
 Figure 22. United States Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Pulmonary Fibrosis Drug Sales Market Share by Country (2020-2031)
 Figure 25. Europe Pulmonary Fibrosis Drug Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Pulmonary Fibrosis Drug Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Pulmonary Fibrosis Drug Revenue Market Share by Region (2020-2031)
 Figure 33. China Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. China Taiwan Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Indonesia Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Thailand Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Malaysia Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Pulmonary Fibrosis Drug Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Pulmonary Fibrosis Drug Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Pulmonary Fibrosis Drug Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Pulmonary Fibrosis Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Pulmonary Fibrosis Drug by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Pulmonary Fibrosis Drug by Type (2020-2031)
 Figure 54. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Pulmonary Fibrosis Drug by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Pulmonary Fibrosis Drug by Application (2020-2031)
 Figure 57. Global Pulmonary Fibrosis Drug Price (US$/Unit) by Application (2020-2031)
 Figure 58. Pulmonary Fibrosis Drug Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Chronic Pain Medical Devices Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0I20198
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Disposable Insulin Pen Needle Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33W11115
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32E19705
Thu Sep 11 00:00:00 UTC 2025

Add to Cart